Clinical Trial Update: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial of Tusamitamab Ravtansine (SAR408701) with pembrolizumab, with or without platinum-based chemotherapy with/without pemetrexed, in non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)
• Tusamitamab Ravtansine (Tusamitamab Ravtansine)

Snippet

Sponsor: Sanofi | Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | Phase 2 | Status: TERMINATED | Results posted: 2025-03-17